A

Aelis Farma SA
PAR:AELIS

Watchlist Manager
Aelis Farma SA
PAR:AELIS
Watchlist
Price: 2.88 EUR 2.13% Market Closed
Market Cap: 39.5m EUR
Have any thoughts about
Aelis Farma SA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-0.3
Current
-16.5
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.3
=
Enterprise Value
2.2m EUR
/
EBITDA
-7.4m EUR
All Countries
Close
Market Cap EV/EBITDA
FR
Aelis Farma SA
PAR:AELIS
35.2m EUR -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 796.6
US
Abbvie Inc
NYSE:ABBV
312.7B USD 15.3
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 17.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 24
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -514.1
AU
CSL Ltd
ASX:CSL
133.6B AUD 20.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 16.2
US
Seagen Inc
F:SGT
39.3B EUR -58.7
NL
argenx SE
XBRU:ARGX
34.5B EUR -104.5
EBITDA Growth
FR
A
Aelis Farma SA
PAR:AELIS
Average EV/EBITDA: 17.2
Negative Multiple: -0.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-0.2
2-Years Forward
EV/EBITDA
0.1
3-Years Forward
EV/EBITDA
-0.2

See Also

Discover More